1. Cancer

Cancer

Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body. Cancers are the consequence of a process of somatic mutation and break the balance controlled by gene expression programs and cellular networks that typically maintain intracellular homeostasis and prevent unnecessary expansion. Cancer hallmarks and important biological processes, such as cell growth, and cellular differentiation, are able to reveal neoplasia, growth and metastasis dissemination.

Cancer Related Products (2341):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-10219
    Rapamycin 53123-88-9 98.98%
    Rapamycin is a specific mTOR inhibitor with IC50 of 0.1 nM.
    Rapamycin
  • HY-13259
    MG-132 133407-82-6 >98.0%
    MG-132 is a potent, non-specific 20S proteasome inhibitor, with IC50 of 24.2 nM for the β5 chymotrypsin-like active site.
    MG-132
  • HY-16658
    Z-VAD-FMK 187389-52-2 >98.0%
    Z-VAD-FMK is a cell-permeable, pan-caspase inhibitor.
    Z-VAD-FMK
  • HY-10108
    LY294002 154447-36-6 99.97%
    LY294002 is a broad-spectrum inhibitor of PI3K, with IC50 of 0.5/0.57/0.97 μM for PI3Kα/δ/β, respectively, also potently inhibits CK2 with IC50 of 98 nM.
    LY294002
  • HY-13030
    (+)-JQ-1 1268524-70-4 99.86%
    (+)-JQ-1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for the first and second bromodomain (BRD4(1/2)).
    (+)-JQ-1
  • HY-70002
    Enzalutamide 915087-33-1 99.20%
    Enzalutamide is an androgen-receptor (AR) antagonist with IC50 of 36 nM in LNCaP cells.
    Enzalutamide
  • HY-70062
    MLN4924 905579-51-3 98.78%
    MLN4924 is a potent and selective NEDD8-activating enzyme (NAE) inhibitor with IC50 of 4.7 nM.
    MLN4924
  • HY-12041
    SP600125 129-56-6 >98.00%
    SP600125 is a broad-spectrum JNK inhibitor for JNK1, JNK2 and JNK3 with IC50 of 40 nM, 40 nM and 90 nM, respectively.
    SP600125
  • HY-19312
    3-Methyladenine 5142-23-4 99.84%
    3-Methyladenine is a selective PI3K inhibitor with IC50 of 25 μM and 60 μM for Vps34 and PI3Kγ, respectively, and it can inhibit all PtdIns3Ks at 10 mM.
    3-Methyladenine
  • HY-12031
    U0126 1173097-76-1 98.03%
    U0126 is a non-ATP competitive MEK inhibitor, with IC50 of 70 nM and 60 nM for MEK1 and MEK2, respectively.
    U0126
  • HY-17559
    Actinomycin D 50-76-0 99.89%
    Actinomycin D inhibits DNA repair with IC50 of 0.42 μM.
    Actinomycin D
  • HY-10162
    Olaparib 763113-22-0 99.65%
    Olaparib is a potent PARP inhibitor with IC50 of 5 and 1 nM for PARP-1 and PARP-2, respectively.
    Olaparib
  • HY-15142
    Doxorubicin hydrochloride 25316-40-9 99.47%
    Doxorubicin hydrochloride is a Topoisomerase II (Top2) catalytic inhibitor, also is a broad spectrum antibiotic used in the treatment of cancers, with IC50 of 374 nM for Hela cells.
    Doxorubicin hydrochloride
  • HY-17394
    Cisplatin 15663-27-1 >98.00%
    Cisplatin is a potent inducer of growth arrest and/or apoptosis in most cell types.
    Cisplatin
  • HY-10583
    Y-27632 dihydrochloride 129830-38-2 98.53%
    Y-27632 dihydrochloride is an ATP-competitive inhibitor of ROCK-I and ROCK-II, with Ki of 220 nM and 300 nM for ROCK-I and ROCK-II, respectively.
    Y-27632 dihydrochloride
  • HY-15772
    AZD-9291 1421373-65-0 99.91%
    AZD-9291 is a third generation irreversible EGFR tyrosine kinase inhibitor with selectivity against mutant versus wild-type forms of EGFR, shows an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M in EGFR recombinant enzyme assay.
    AZD-9291
  • HY-13418
    Dorsomorphin dihydrochloride 1219168-18-9 99.73%
    Dorsomorphin dihydrochloride is a potent and selective AMPK inhibitor, that is competitive with ATP, with Ki of 109±16 nM in the absence of AMP.
    Dorsomorphin dihydrochloride
  • HY-13316
    Mitomycin C 50-07-7 98.51%
    Mitomycin C is a DNA-damaging agent and small-molecule inhibitor effectively sensitize cancer cells to tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL).
    Mitomycin C
  • HY-10227
    Bortezomib 179324-69-7 99.72%
    Bortezomib is a potent 20S proteasome inhibitor with Ki of 0.6 nM.
    Bortezomib
  • HY-10431
    SB-431542 301836-41-9 99.24%
    SB-431542 is a potent and selective inhibitor of ALK5 and ALK4 with IC50 values of 94 nM and 14 nM, respectivelly, and is also an inhibitor of TGF-β Receptor.
    SB-431542